Clinical trials and evidence
Clinical trials and real-world evidence support evidence-based medicine in healthcare, playing a pivotal role in validating and advancing medical treatments and interventions. Clinical trials assess the efficacy and safety of new drugs and therapies, with real-world evidence providing data to inform clinical and regulatory decisions based on empirical data.
Top Stories
-
Podcast
18 Sep 2024
Exploring chronic disease management trends, strategies
Chronic disease management and prevention strategies are of increasing importance as chronic conditions increase in prevalence. Continue Reading
-
News
26 Aug 2024
Long COVID effects in adolescents, young children vary
NIH-funded research through the RECOVER initiative revealed that long COVID symptoms among pediatric patients varied from sleepiness to headaches, underscoring vaccine importance. Continue Reading
-
News
18 May 2021
Merck’s Keytruda Helps Patients with High-Risk Breast Cancer
A Phase 3 clinical trial found that Keytruda met its primary endpoint of event-free survival when compared with chemotherapy alone in patients with high-risk triple-negative breast cancer. Continue Reading
-
News
17 May 2021
Top mRNA COVID-19 Vaccines 94% Effective, New CDC Data Shows
The real-word data comes from a CDC study of healthcare personnel who received two doses of either Pfizer’s or Moderna’s mRNA COVID-19 vaccine. Continue Reading
-
News
13 May 2021
Eli Lilly Taps saRNA Research Tech from MiNA for Drug Discovery
The companies will leverage MiNA’s small activating RNA (saRNA) research technology platform to research up to five novel drug candidates that address specific therapeutic areas. Continue Reading
-
News
12 May 2021
Eli Lilly Takes on Digital Diabetes Care Management
Along with DexCom, Glooko Inc, myDiabby Healthcare, and Roche, Eli Lilly will streamline diabetes care management through automated data collection for insulin dose tracking. Continue Reading
-
News
11 May 2021
Pfizer COVID-19 Vaccine Can be Used in Adolescents, FDA Says
FDA has amended the original emergency use authorization for Pfizer COVID-19 vaccine to include adolescents 12 through 15 years of age. Continue Reading
-
News
10 May 2021
NHS Rolls Out 3D Imaging Technology for Heart Disease Diagnosis
The 3D imaging technology turns a regular CT scan of the heart into a 3D image, which allows doctors to diagnose life-threatening coronary heart disease in 20 minutes. Continue Reading
-
News
06 May 2021
MedRhythm Begins Trial to Study Digital Therapeutics for Stroke
In partnership with UMass Memorial Healthcare, the trial studying digital therapeutics for stroke will be split in two phases, one in the hospital setting and one post-discharge. Continue Reading
-
News
04 May 2021
FDA Greenlights AstraZeneca’s Farxiga for Chronic Kidney Disease
In a study, 197 of the 2,152 patients who received AstraZeneca’s Farxiga had at least one composite endpoint event compared to 312 of the 2,152 patients who received a placebo. Continue Reading
-
News
04 May 2021
Moderna Increases Global 2022 COVID-19 Vaccine Capacity to 3B
The global COVID-19 vaccine capacity will be dependent upon the mix between Moderna’s authorized vaccine and lower doses of its variant booster candidates and pediatric vaccines. Continue Reading
-
News
28 Apr 2021
Few Drugs Make Half of Medicare Prescription Drug Spending
A small number of drugs accounted for a large share of Medicare prescription drug spending in 2019, and those drugs generally didn’t have generic or biosimilar competitors. Continue Reading
-
News
27 Apr 2021
Early COVID-19 Treatments Elicited No Real Benefits in Patients
Researchers found that there was no significant benefit of using COVID-19 treatments hydroxychloroquine and lopinavir-ritonavir in hospitalized patients. Continue Reading
-
News
26 Apr 2021
COVID-19 Mortality Dropped as Drug Therapies Emerged
A new study suggests that drug therapies for COVID-19 as well as more clinical experience treating the virus may have contributed to lower COVID-19 mortality rates. Continue Reading
-
News
21 Apr 2021
FDA Rescinds EUA for Eli Lilly’s Monoclonal COVID-19 Antibody
The agency determined that the known benefits of the COVID-19 antibody alone no longer outweigh the known and potential risks for its authorized use. Continue Reading
-
News
21 Apr 2021
FDA Approves Opdivo as First Immunotherapy for Gastric Cancer
A randomized trial found that the median survival for patients treated with the immunotherapy lived over two months longer than those who received chemotherapy alone. Continue Reading
-
News
19 Apr 2021
Trial Updates from Moderna’s mRNA, RSV Vaccine Candidates
Moderna announced updates from a Phase 1 study of its RSV vaccine candidate, as well as a Phase 2 study of its mRNA vaccine candidate. Continue Reading
-
News
16 Apr 2021
China Approves AstraZeneca’s Non-Small Cell Lung Cancer Drug
AstraZeneca’s prescription drug, Tagrisso, is the only targeted medicine to show efficacy in the treatment of early-stage non-small cell lung cancer in a global trial. Continue Reading
-
News
15 Apr 2021
Gilead Stops Phase 3 Remdesivir Trial in COVID-19 Patients
Gilead no longer believes that developing the COVID-19 treatment as a multiple-day injection in a healthcare setting addresses the unmet need for non-hospitalized patients. Continue Reading
-
News
14 Apr 2021
Medical AI Device Evaluation Process Could Mask Vulnerabilities
A majority of data test sets from FDA-approved medical AI devices were collected and evaluated before device deployment rather than concurrently, which can mask vulnerabilities. Continue Reading
-
News
14 Apr 2021
FDA Approves Marketing of AI Medical Device to Detect Colon Cancer
The medical device, GI Genius, uses AI to highlight portions of the colon where there may be a potential lesion for real-time detection during a colonoscopy. Continue Reading
-
News
09 Apr 2021
Data Reveals High Vaccine Efficacy for Moderna, Pfizer Doses
New data reveals high vaccine efficacy for both the Moderna and Pfizer-BioNTech vaccines, while clinical trial results hamper baricitinib use for COVID patients. Continue Reading
-
News
05 Apr 2021
NIH Launches COVID Variant Trial; Pfizer Releases New Data
In other COVID-19 vaccine news, J&J is on track to meet its vaccine distribution goal and GSK will help Novavax manufacture its vaccine. Continue Reading
-
News
02 Apr 2021
TCR2 Establishes Cell Therapy Manufacturing Facility in MD
TCR2 aims to treat several thousand cancer patients annually through its newly established cell therapy manufacturing facility. Continue Reading
-
News
01 Apr 2021
FDA Requests More Data from Merck on Keytruda for Breast Cancer
FDA officials stated that further data is needed from Merck’s Phase 3 trial of its monoclonal antibody, Keytruda, before a regulatory decision is made. Continue Reading
-
News
31 Mar 2021
Pfizer-BioNTech COVID-19 Vaccine 100% Effective in Adolescents
The Phase 3 trial enrolled 2,260 adolescents aged 12 to 15 years old and found that the overall results exceeded those recorded earlier in vaccinated participants 16 to 25 years of age. Continue Reading
-
News
31 Mar 2021
Real-World Evidence Confirms Efficiency of mRNA COVID-19 Vaccines
A CDC study used real-world evidence to find that both Pfizer and Moderna’s COVID-19 vaccines reduced risk of infection 90% two or more weeks after the second dose. Continue Reading
-
News
30 Mar 2021
Children Produce More COVID-19 Antibodies, Study Finds
A cross-sectional study found that younger children exhibited notably higher COVID-19 antibody production than adolescents and young adults. Continue Reading
-
News
30 Mar 2021
Moderna Studies COVID-19 Vaccine Candidate in Pediatric Population
The Phase 2/3 study will evaluate Moderna’s COVID-19 vaccine candidate in 6,750 healthy pediatric participants less than 12 years of age. Continue Reading
-
News
26 Mar 2021
COVID-19 Antigen Tests Prove More Accurate in Symptomatic Patients
While the COVID-19 antigen tests correctly identified 72%of people who were infected with the virus, the test only correctly identified 58% of asymptomatic patients. Continue Reading
-
News
25 Mar 2021
AstraZeneca COVID-19 Vaccine 76% Effective in Phase 3 Trial
The COVID-19 vaccine showed comparable efficacy results across ethnicity and age, with 85% efficacy in participants aged 65 years and over. Continue Reading
-
News
24 Mar 2021
Eli Lilly’s COVID-19 Antibody Reduces Hospitalizations by 87%
The second positive Phase 3 trial readout for the COVID-19 antibody combination supports the use of bamlanivimab at 700 mg and etesevimab at 1400 mg. Continue Reading
-
News
24 Mar 2021
COVID-19 Hospitalizations Spark Overuse of Antibiotic Concerns
A Pew Charitable Trusts study found that 52% of COVID-19 hospitalizations resulted in antibiotic prescribing even though just 20% of those admitted were diagnosed with infection. Continue Reading
-
News
23 Mar 2021
GSK COVID-19 Antibody Elicits 85% Drop in Hospitalizations, Deaths
A Phase 3 trial found an 85% reduction in hospitalization or death in 583 non-hospitalized patients who received the COVID-19 antibody compared to a placebo. Continue Reading
-
News
22 Mar 2021
Real-World Evidence Confirms Pfizer COVID-19 Vaccine Effectiveness
Real-world evidence gathered by the Israel Ministry of Health found lower coronavirus disease rates in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 vaccine. Continue Reading
-
News
19 Mar 2021
UK and EU Reaffirm Safety of AstraZeneca’s COVID-19 Vaccine
MHRA and EMA both stated that AstraZeneca’s COVID-19 vaccine continues to outweigh the risks and that vaccinations should continue. Continue Reading
-
News
19 Mar 2021
Eli Lilly, Biolojic to Develop Antibody Therapies for Diabetes
The partnership will leverage Biolojic’s artificial intelligence-based platform to discover and develop multi-specific antibody therapies for the treatment of diabetes. Continue Reading
-
News
16 Mar 2021
FDA Authorizes Sequencing-Based COVID-19 Diagnostic Test
The authorization was based on a trial showing that the COVID-19 diagnostic test elicited sensitivity of 97.1% and a specificity of 100%. Continue Reading
-
News
15 Mar 2021
RNA-Based Vaccine May Fully Immunize Against Malaria
Researchers created an RNA-based vaccine that allows the human body to produce the needed T-cells and completely immunize against malaria. Continue Reading
-
News
08 Mar 2021
GSK Antibody Helps Combat Respiratory Failure from COVID-19
A study found that 65.1% of patients 70 years of age and older were alive and free of COVID-19-induced respiratory failure 28 days after treatment with the antibody. Continue Reading
-
News
08 Mar 2021
Moderna Ships Doses of Variant-Specific COVID-19 Vaccine to NIH
An NIH Phase 1 trial will uncover if Moderna’s variant-specific COVID-19 vaccine candidate can boost immunity against a variant found in South Africa. Continue Reading
-
News
05 Mar 2021
Best Practices for Addressing Diversity in Clinical Trials
Diversity in clinical trials is key to creating treatments that cater to a wide range of populations, but major barriers oftentimes keep researchers from reaching certain populations. Continue Reading
-
News
04 Mar 2021
Study Finds Diversity in Clinical Trials Still Lacking
Black, Hispanic, and American Indian and Alaskan Natives are underrepresented, indicating a lack of diversity in clinical trials in the US, researchers stated. Continue Reading
-
News
04 Mar 2021
Pfizer, BioNTech Submit COVID-19 Vaccine Stability Data to FDA
The stability data highlights that the company’s COVID-19 vaccine can be stored at higher temperatures than previously determined, making vaccine distribution easier. Continue Reading
-
News
02 Mar 2021
Pfizer to Study COVID-19 Vaccine in Pregnant Women
The randomized study will assess the safety and tolerability of two doses of the Pfizer-BioNTech COVID-19 vaccine in healthy pregnant women. Continue Reading
-
News
01 Mar 2021
bluebird bio Suspends Studies of Sickle Cell Disease Gene Therapy
The company placed the studies on temporary suspension after a patient who was treated with its gene therapy over 5 years ago was diagnosed with acute myeloid leukemia. Continue Reading
-
News
25 Feb 2021
FDA Analysis Finds J&J’s COVID-19 Vaccine Safe, Effective
Phase 3 data submitted to FDA showed that a single-dose of the COVID-19 vaccine was 66.9% effective 14 days after vaccination and 66.% effective 28 days after vaccination Continue Reading
-
News
24 Feb 2021
GSK Doses First Patient in Phase 3 Study of RSV Vaccine Candidate
The study will enroll 1,650 adults 60 years and older to study the long-term immune response of GSK’s RSV vaccine candidate three years following vaccination. Continue Reading
-
News
16 Feb 2021
AbbVie, Caribou Biosciences to Develop CAR-T Cell Therapies
The companies will research and develop two new CAR-T cell therapies specified by AbbVie using Caribou’s next-generation genome editing and cell therapy technologies. Continue Reading
-
News
11 Feb 2021
FDA Approves Bristol Meyers Squibb CAR T Cell Therapy for Lymphoma
A clinical trial that found complete remission rate after treatment with the CAR T cell therapy was 54%. Continue Reading
-
News
11 Feb 2021
Siemens Healthineers Receives CE Mark for COVID-19 Antigen Test
The point-of-care COVID-19 antigen test does not require laboratory tools or specialized lab personnel and delivers results in just 15 minutes. Continue Reading
-
News
09 Feb 2021
Roche to Launch Self-Administered COVID-19 Antigen Test
The COVID-19 antigen test was designed to be faster and less invasive to address patient discomfort, especially in sensitive individuals including children, the elderly, and individuals with disabilities. Continue Reading
-
News
05 Feb 2021
Virtual Clinical Trial Kicks Off in NY to Study COVID-19 Therapy
The fully virtual clinical trial will provide patients with an Apple iPad and Bluetooth-enabled tools to study the safety and efficacy of a COVID-19 therapy from their own homes. Continue Reading
-
News
04 Feb 2021
AstraZeneca’s COVID-19 Vaccine 82% Effective After Second Dose
The COVID-19 vaccine elicited a vaccine efficiency of 76% after the first dose and an 82% efficacy after an inter-dose interval of over 12 weeks, AstraZeneca said. Continue Reading
-
News
03 Feb 2021
Eli Lilly’s COVID-19 Antibodies Reduce Hospitalizations by 70%
The combination of the COVID-19 antibodies also improved all key secondary endpoints, including reducing viral loads and enhancing symptom resolution, the company reported. Continue Reading
-
News
02 Feb 2021
First Patient Dosed in Trial of Two Separate COVID-19 Therapies
The study of the COVID-19 therapies from Eli Lilly and Company and Vir Biotechnology-GSK, is the first time antibodies from separate companies will be evaluated against the coronavirus. Continue Reading
-
News
01 Feb 2021
GSK, Novartis to Study Genetic Diversity for Drug Development
The pharma companies intend for the $3.6M research project to determine the impact genetic diversity in Africa has on malaria and TB drug responses and inform future drug development. Continue Reading
-
News
01 Feb 2021
J&J’s COVID-19 Vaccine 66% Effective in Moderate, Severe Cases
The single-dose COVID-19 vaccine was more effective at preventing severe disease, Johnson & Johnson reported. Continue Reading
-
News
28 Jan 2021
Moderna Doses First Patient in Japanese Study of COVID-19 Vaccine
The placebo-controlled Phase 1/2 study will enroll 200 participants aged 20 years and older to evaluate the safety and immunogenicity of two doses of Moderna’s COVID-19 vaccine. Continue Reading
-
News
26 Jan 2021
Merck Terminates Development of COVID-19 Vaccine Candidates
Although the COVID-19 vaccine candidates were generally well-tolerated in Phase 1 clinical studies, immune responses were lesser than those reported for other candidates. Continue Reading
-
News
26 Jan 2021
Pfizer’s COVID-19 Vaccine Elicits Antibodies Against UK Strain
After proving effective against a primary mutation of the South African strain, Pfizer and BioNTech are hopeful that their COVID-19 vaccine will combat the recently discovered UK strain. Continue Reading
-
News
25 Jan 2021
Gilead, Vir Biotechnology to Evaluate Novel Therapies for HBV
The companies will initiate a Phase 2 trial evaluating novel therapies for both treatment-experienced and treatment-naïve individuals living with hepatitis B virus. Continue Reading
-
News
21 Jan 2021
Experts Torn Over Half-Dosing Moderna, Pfizer COVID-19 Vaccines
Experts are torn over whether half-dosing Moderna and Pfizer-BioNTech’s respective COVID-19 vaccines is beneficial to vaccinate more individuals or premature and harmful in the long-run. Continue Reading
-
News
19 Jan 2021
Second COVID-19 Antibody from Vir, GSK Enters Phase 1b Trial
VIR and GSK’s second COVID-19 antibody, VIR- 7832, will be evaluated in a Phase 1b clinical trial after preclinical data showed it had potential to treat patients infected with the coronavirus. Continue Reading
-
News
18 Jan 2021
How Technology is Helping One Health System Distribute COVID-19 Vaccines
At LifeBridge Health, innovative technologies are playing a critical role in COVID-19 vaccine distribution including patient engagement, appointment reminders, follow-up for second doses, and side effect monitoring. Continue Reading
-
News
13 Jan 2021
Kaiser to Track Serious Adverse Events From COVID-19 Vaccination
Kaiser analysts will track patient electronic patient records to identify serious adverse reactions after COVID-19 vaccination. Continue Reading
-
News
12 Jan 2021
NIH Initiates Trial to Evaluate COVID-19 Antibody Therapy
Researchers will observe if the COVID-19 antibody therapy from Brii Biosciences can safely reduce the duration of COVID-19 symptoms, and eliminate the presence of viral RNA in the body. Continue Reading
-
News
12 Jan 2021
First Patient Treated in Study of Biogen’s Rare Disease Drug
The Phase 4 study will be conducted at 20 sites globally and enroll 60 children up to three years of age who may benefit from the rare disease drug after failing to respond to previous treatment. Continue Reading
-
News
11 Jan 2021
Pfizer Kicks Off Phase 3 Trial for Rare Disease Gene Therapy
The Phase 3 study aims to determine whether a rare disease gene therapy elicits any changes in motor functions among those with Duchenne muscular dystrophy one year after baseline. Continue Reading
-
News
29 Dec 2020
Pfizer Provides Data From German Trial of COVID-19 Vaccine
The trial found that all 37 patients immunized with Pfizer and BioNTech’s COVID-19 vaccine, BNT162b2, showed a broad immune response with SARS-CoV-2 specific neutralizing antibodies. Continue Reading
-
News
22 Dec 2020
More Positive Data Released for Pfizer-BioNTech COVID-19 Vaccine
A study published in NEJM found that Pfizer and BioNTech’s mRNA COVID-19 vaccine met both primary efficacy endpoints, with almost 100% probability of true vaccine efficiency over 30%. Continue Reading
-
News
17 Dec 2020
Sanofi, GSK Halt Adjuvanted COVID-19 Vaccine Program
GSK and Sanofi delayed their adjuvanted COVID-19 vaccine program after a clinical trial found low immune response in older adults. Continue Reading
-
News
17 Dec 2020
AstraZeneca Reports Positive Results in Cancer Drug Clinical Trial
The Phase 2 clinical trial found that mantle cell lymphoma patients treated with AstraZeneca’s cancer drug, Calquence, remained progression free for an average of 22 months. Continue Reading
-
News
15 Dec 2020
Moderna Launches Study of COVID-19 Vaccine in Adolescents
The study will evaluate the safety and immunogenicity of two vaccinations of Moderna’s mRNA-based COVID-19 vaccine in 3,000 participants aged 12 to under 18 years of age. Continue Reading
-
News
14 Dec 2020
Roche to Include COVID-19 Antibody Test in Moderna’s Trials
Including the COVID-19 antibody test will offer easier quantitative measurement of antibodies and help establish a correlation between vaccine-induced protection and levels of anti-receptor binding domain antibodies, the companies said. Continue Reading
-
News
14 Dec 2020
Cerner Invests in Elligo to Boost Access to Clinical Trials
Cerner’s investment in the integrated research organization seeks to broaden provider access to clinical trials and reduce the costs associated with bringing therapies to market. Continue Reading
-
News
11 Dec 2020
Pfizer Reports Positive Data for Multiple Myeloma Antibody Drug
The multiple myeloma antibody drug elicited an overall response rate of 80% among 20 patients treated in cohorts across efficacious dose ranges of 215 to 1,000 μg/kg weekly. Continue Reading
-
News
10 Dec 2020
Ovid Therapeutics Rare Disease Drug Fails in Phase 3 Study
The rare disease drug, OV101, elicited a 0.7 point improvement in Angelman syndrome over baseline, while placebo showed an 0.8 point improvement. Continue Reading
-
News
10 Dec 2020
Eli Lilly, UnitedHealth Group Launch Study of COVID-19 Antibody
The study of Eli Lilly & Company’s COVID-19 antibody, LY-CoV555, will identify and treat nearly 500,000 high-risk individuals infected with the virus under real-world conditions. Continue Reading
-
News
03 Dec 2020
GSK Initiates Phase 3 Study of RSV Maternal Vaccine Candidate
The Phase 3 study will enroll 10,000 pregnant women to uncover if a single dose of the RSV vaccine candidate can prevent lower respiratory tract infections in newborns. Continue Reading
-
News
01 Dec 2020
Second Analysis Finds Moderna’s COVID-19 Vaccine 94.1% Effective
The continued analysis of the Phase 3 study of Moderna’s COVID-19 vaccine found that it continues to be generally well tolerated with no safety concerns identified to date. Continue Reading
-
News
25 Nov 2020
AstraZeneca’s COVID-19 Vaccine Meets Primary Endpoints
AstraZeneca’s COVID-19 vaccine was highly effective in preventing coronavirus in UK and Brazil trials, and no hospitalization or severe cases of the disease were reported in participants Continue Reading
-
News
25 Nov 2020
Siemens Healthineers Launches Improved COVID-19 Antibody Test
Research shows that the COVID-19 antibody test helps providers determine whether a patient's immune system is producing the right antibodies to stop or prevent the virus. Continue Reading
-
News
24 Nov 2020
J&J Launches Second Global Trial of Lead COVID-19 Vaccine
The trial will study the efficacy of a two-dose regimen of Johnson & Johnson’s COVID-19 vaccine candidate, Ad26.COV2.S, in nearly 30,000 participants globally. Continue Reading
-
News
23 Nov 2020
Pfizer’s COVID-19 Vaccine Is Actually 95% Effective, New Data Shows
Results of the now concluded Phase 3 study showed that the mRNA COVID-19 vaccine is more effective than initial data showed at 95 percent effective. Continue Reading
-
News
23 Nov 2020
Placebo Elicits Same Side Effects As Cholesterol-Lowering Statins
Patients experienced intolerable side effects even when they took a placebo, suggesting that the side effects of cholesterol-lowering statins may be psychological rather than pharmacological. Continue Reading
-
News
20 Nov 2020
Comparing COVID-19 Vaccine Candidates from Pfizer, Moderna
Both Moderna and Pfizer’s lead mRNA COVID-19 vaccines were over 90% effective in clinical trials, but they have a few major differences that must be addressed before being FDA approved. Continue Reading
-
News
19 Nov 2020
New PhRMA Guidelines Aim to Improve Clinical Trial Diversity
The guidelines on clinical trial diversity address building trust in clinical trials within the Black community, reducing barriers to trial access, and enhancing general information on diversity and inclusion. Continue Reading
-
News
17 Nov 2020
GSK, Medicago Start Phase 2 Trial of Adjuvanted COVID-19 Vaccine
The adjuvanted COVID-19 vaccine will advance into Phase 2 clinical trials based on positive Phase 1 results, which showed high immune responses in infected patients. Continue Reading
-
News
16 Nov 2020
Early Analysis Finds Moderna’s COVID-19 Vaccine Is 95% Effective
Moderna’s mRNA COVID-19 vaccine candidate met statistical criteria pre-specified in the study protocol for efficacy in a majority of US participants. Continue Reading
-
News
11 Nov 2020
Humanigen, DoD to Develop COVID-19 Antibody Treatment
Researchers estimated that there were 37% more recoveries in patients who received the COVID-19 antibody treatment, lenzilumab, versus current standard of care. Continue Reading
-
News
09 Nov 2020
Pfizer’s COVID-19 Vaccine Is Over 90% Effective, Early Data Shows
The company’s COVID-19 vaccine candidate, BNT162b2, was found to be more than 90%effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection. Continue Reading
-
News
06 Nov 2020
Novartis to Develop Direct-Acting COVID-19 Antiviral Therapies
Novartis has been granted the option to in-license global rights of two direct-acting COVID-19 antiviral therapies demonstrating efficacy against the novel coronavirus. Continue Reading
-
News
03 Nov 2020
States Detail Specific Use of Abbott’s BinaxNOW COVID-19 Tests
Four weeks after HHS said it would deploy 150 million BinaxNOW COVID-19 tests, states said they will provide the tests to local health departments, schools and universities, and nursing homes. Continue Reading
-
News
02 Nov 2020
Regeneron’s COVID-19 Antibody Cocktail Reduces Virus Levels
The COVID-19 antibody cocktail reduced coronavirus-related medical visits by 57% and related medical visits by 72% in patients with more than one risk factor. Continue Reading
-
News
29 Oct 2020
Thermo Fisher Scientific Supports Direct-to-Patient Clinical Trials
The company’s clinical trial service offerings now include clinical site-to-patient, pharmacy-to-patient, and depot-to-patient services to allow for medication delivery directly to patient homes. Continue Reading
-
News
28 Oct 2020
AstraZeneca Resumes Phase 3 US Trial for its COVID-19 Vaccine
After reviewing safety data from clinical trials evaluating AstraZeneca’s COVID-19 vaccine, AZD122, regulators deemed it safe to resume all trials. Continue Reading
-
News
27 Oct 2020
Johnson & Johnson Resumes Phase 3 Trial of COVID-19 Vaccine
Johnson & Johnson resumes the Phase 3 trial after finding no evidence that its COVID-19 vaccine candidate caused a “serious medical event” in one study participant in mid-October. Continue Reading
-
News
22 Oct 2020
CRISPR’s CAR-T Cell Therapy Shows Promise in Clinical Trial
Out of 12 patients with relapsed or refractory non-Hodgkin lymphoma, the cell therapy elicited early evidence of dose-dependent anti-tumor activity and no dose-limiting toxicities were found. Continue Reading
-
News
21 Oct 2020
Thermo Fisher Scientific to Expand At-Home COVID-19 Testing
The company’s COVID-19 testing combo kit is now authorized for use with Everlywell’s home testing kit, which allows individuals to self-test when approved by a health official. Continue Reading
-
News
21 Oct 2020
Sanofi’s mRNA COVID-19 Vaccine Elicits High Antibody Levels
In preclinical studies, the mRNA COVID-19 vaccine candidate showed promising neutralizing antibodies against the virus, with levels notably higher than those observed in infected patients. Continue Reading
-
News
20 Oct 2020
NIH Launches Trial to Test Immune Modulator Drugs for COVID-19
The trial will uncover if immune modulator drugs from Johnson & Johnson, Bristol Myers Squibb, and Abbvie can restore balance to overactive immune systems in COVID-19 patients. Continue Reading